Harnessing the PD-1 Pathway in Myelodysplastic Syndrome

Am J Ther. 2018 Nov/Dec;25(6):e711-e712. doi: 10.1097/MJT.0000000000000728.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Anemia, Refractory, with Excess of Blasts / blood
  • Anemia, Refractory, with Excess of Blasts / diagnosis
  • Anemia, Refractory, with Excess of Blasts / drug therapy*
  • Anemia, Refractory, with Excess of Blasts / pathology
  • Antineoplastic Agents, Immunological / pharmacology
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Biopsy
  • Bone Marrow / pathology
  • Female
  • Hemoglobins / analysis
  • Humans
  • Leukocyte Count
  • Nivolumab / pharmacology
  • Nivolumab / therapeutic use*
  • Platelet Count
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / metabolism
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • Hemoglobins
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab